Broad panel genetic testing found effective for diagnosing patients with kidney disease

A kidney disease panel for 382 genes yielded a high success rate and was effective in identifying monogenic variants underlying inherited kidney diseases, according to data published in the American Journal of Nephrology.

“Recently, Natera Inc. developed a next-generation sequencing (NGS)-based broad panel test for the identification of monogenic causes of chronic kidney disease. This panel encompasses genes associated with disorders spanning multiple types of kidney diseases, including cystic, tubulointerstitial, glomerular, tubular and structural disorders,” Anthony J. Bleyer, MD, from Wake Forest School of Medicine in Winston Salem, South Carolina, and colleagues wrote. Read more.